top: add ref
Okumaya devam et...
← Previous revision | Revision as of 03:24, 30 April 2024 |
| Line 90: | Line 90: |
| '''Sotatercept''', sold under the brand name '''Winrevair''' is a [[medication]] used for the treatment of [[pulmonary arterial hypertension]].<ref name="Winrevair FDA label" /> It is an [[activin]] signaling inhibitor,<ref name="Winrevair FDA label" /> based on the extracellular domain of the [[activin type 2 receptor]] expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc).<ref>{{cite journal | last=Doggrell | first=Sheila A | title=Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)? | journal=Expert Opinion on Biological Therapy | volume=23 | issue=7 | date=July 2023 | pmid=37269300 | doi=10.1080/14712598.2023.2221784 | pages=589–593}}</ref> It is given by [[subcutaneous injection]].<ref name="Winrevair FDA label" /> | '''Sotatercept''', sold under the brand name '''Winrevair''' is a [[medication]] used for the treatment of [[pulmonary arterial hypertension]].<ref name="Winrevair FDA label" /> It is an [[activin]] signaling inhibitor,<ref name="Winrevair FDA label" /> based on the extracellular domain of the [[activin type 2 receptor]] expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc).<ref>{{cite journal | last=Doggrell | first=Sheila A | title=Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)? | journal=Expert Opinion on Biological Therapy | volume=23 | issue=7 | date=July 2023 | pmid=37269300 | doi=10.1080/14712598.2023.2221784 | pages=589–593}}</ref> It is given by [[subcutaneous injection]].<ref name="Winrevair FDA label" /> |
| Sotatercept was approved for medical use in the United States in March 2024.<ref name="Winrevair FDA label" /><ref>{{cite press release | title=FDA Approves Merck's Winrevair (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) | publisher=Merck | via=Business Wire | date=27 March 2024 | url=https://www.businesswire.com/news/h...monary-Arterial-Hypertension-PAH-WHO*-Group-1 | access-date=27 March 2024}}</ref> | Sotatercept was approved for medical use in the United States in March 2024.<ref name="Winrevair FDA label" /><ref>{{cite web | title=Novel Drug Approvals for 2024 | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 April 2024 | url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 | access-date=30 April 2024 | archive-date=30 April 2024 | archive-url=https://web.archive.org/web/2024043...-drug-approvals-fda/novel-drug-approvals-2024 | url-status=live }}</ref><ref>{{cite press release | title=FDA Approves Merck's Winrevair (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) | publisher=Merck | via=Business Wire | date=27 March 2024 | url=https://www.businesswire.com/news/h...monary-Arterial-Hypertension-PAH-WHO*-Group-1 | access-date=27 March 2024}}</ref> |
| == Medical uses == | == Medical uses == |
Okumaya devam et...